Assesment of Treatment Outcomes of Aquired Aplastic Anemia in Children : A Retrospective and Prospective Cohort
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Aplastic Anaemia (AA). Basic parameters: 1 year — 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this observational study is to to assess of treatment Outcomes of Aquired Aplastic Anemia in children
Detailed description
This study will be conducted to investigate the clinical outcomes, and treatment modalities of patients diagnosed with aquired aplastic anaemia at Assiut University children Hospital
The main question it aims to answer is:
Primary outcome measures
- To evaluate the treatment outcomes of children diagnosed with aplastic anemia. [Time frame: July 2023-July 2026]
Secondary outcome measures (1)
- To assess response rates to various treatment modalities, including: oImmunosuppressive therapy (IST) oHematopoietic stem cell transplantation (HSCT) oSupportive care only [Time frame: July 2023_July 2026]
Eligibility criteria
Inclusion criteria
- Children aged 1-18 years diagnosed with acquired aplastic anemia, as confirmed by bone marrow examination and fulfilling diagnostic criteria (e.g., bone marrow cellularity <25% and at least two of the following: absolute neutrophil count <500/μL, platelet count <20,000/μL, absolute reticulocyte count <60,000/μL)123.
- The bone marrow biopsy should be compitable with diagnosis
- Diagnosed and/or treated at Assiut University Children's Hospital between Agust 2023 and Augst 2026.
- Patients with complete medical records, including diagnostic, laboratory, and treatment data
Exclusion criteria
- Patients with inherited bone marrow failure syndromes (e.g., Fanconi anemia, dyskeratosis congenita) as confirmed by genetic testing or family history21.
- Patients with incomplete or missing essential data in their medical records.
- Patients diagnosed outside the specified study period or managed primarily at other institutions.
- Patinets with neoplastic or granulomatous disease involving the bone marrow, systemic lupus erythematosus, AIDS, hypersplenism or other conditions associated with pancytopenia such as myelodysplastic syndrome,and paroxysmal nocturnal hemoglobinuria.
- Patients exposed to antineoplastic chemotherapy or radiotherapy were excluded
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07131878 · Aquired Aplastic Anemia ttt